Daily Derm Times: July 31, 2025

To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.

Clinical Community Forms Around Shared AD Challenges

At a recent Dermatology Times Case-Based Roundtable, attendees discussed several challenging AD cases.

Soligenix Reports Positive Phase 2a Data in Behçet’s Disease

The open-label trial showed dusquetide produced similar results to apremilast in reducing oral ulcers, pain, and ulcer duration.

Liza O’Dowd, MD, Discusses What Sets Icotrokinra Apart in Psoriasis Treatment Following NDA Submission

O'Dowd discusses J&J's recent NDA submission for icotrokinra in psoriasis.

How One Dermatologist is Revolutionizing Sun Care to Protect a New Generation

Whitney Hovenic, MD, highlights alarming trends in Gen Z's sun protection habits and introduces SPOOGE, a new sunscreen brand promoting skin health.

Common Sunscreen Allergens: What to Watch For

Kolansky identifies oxybenzone and fragrances as leading causes of sunscreen allergies.

Derm Dispatch: Adam Friedman, MD, FAAD, Unpacks the Science Behind CBD’s Role in UV Protection

Renata Block, DMSc, MMS, PA-C, interviews Adam Friedman, MD, FAAD, about his research into cannabidiol’s photoprotective potential, clinical trial design, and future directions.

Q&A with Jesse Lewin, MD, FACMS: Celebrating 10 Years of Innovations in Skin Cancer at Mount Sinai

Discover how the Kimberly and Eric J. Waldman Melanoma and Skin Cancer Center at Mount Sinai leads in innovative skin cancer care and research, celebrating a decade of excellence.

Leveraging Topicals to Address Severe Itch in Pediatric Atopic Dermatitis

In a discussion on pediatric AD management, Shanna Miranti, MPAS, PA-C, emphasized the enduring role of topical treatments for residual itch and flares, and highlighted the importance of rapid-acting agents such as ruxolitinib cream.

BMS Pursues Global Approval for Deucravacitinib for PsA

Deucravacitinib-treated patients achieved superior clinical responses compared to placebo at week 16 in both trials.